Previous Article | Next Article ![]()
J. Virol., Mar 1997, 1766-1775, Vol 71, No. 3
AL Kirchmaier and B Sugden
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is required in trans to
support replication of the EBV genome once per cell cycle via the latent
origin of replication, oriP. EBNA-1 can also activate transcription on
binding to the family of repeats of oriP to enhance some heterologous as
well as native EBV promoters. We have made and screened derivatives of
EBNA-1 for the ability to act as inhibitors of wild-type EBNA-1. These
derivatives lack the linking or the retention functions of EBNA-1 and were
analyzed for the residual ability to activate transcription and
replication. We have identified derivatives of EBNA-1 that can inhibit up
to 98% of wild-type EBNA-1's activities. We have also identified one
derivative of EBNA-1 with only two of EBNA- 1's three linking domains which
can support transcription and replication inefficiently.
Copyright © 1997, American Society for Microbiology
Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison 53706, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|